patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_983699 | REC_0012401 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 8.3 | 68 | male | 1 | 17 | 5.8 | 2 | osimertinib 80 mg daily | 35.9 | true | MSS | 2026-03-15T05:35:59.964728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590483 | REC_0012402 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 5.9 | 64 | female | 1 | 9 | 4.5 | 5 | entrectinib 600 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:59.964967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992458 | REC_0012403 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14 | 57 | female | 0 | 11 | 6 | 5 | entrectinib 600 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:35:59.965311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660553 | REC_0012404 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.6 | 72 | female | 2 | 19 | 5.8 | 5 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:59.965596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889962 | REC_0012405 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 9 | 73 | female | 1 | 25 | 5 | 6 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:59.965841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503411 | REC_0012406 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.1 | 63 | male | 0 | 5 | 6.3 | 6 | osimertinib 80 mg daily | 9.7 | true | MSS | 2026-03-15T05:35:59.966089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466682 | REC_0012407 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 13.1 | 70 | female | 2 | 16 | 6.2 | 1 | pembrolizumab 200 mg q3w | 18.4 | false | MSI-H | 2026-03-15T05:35:59.966354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422771 | REC_0012408 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 13.6 | 53 | female | 0 | 0 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 28.4 | true | MSS | 2026-03-15T05:35:59.966609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716443 | REC_0012409 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 6.2 | 60 | female | 1 | 15 | 7.2 | 2 | pembrolizumab 200 mg q3w | 17.3 | false | MSS | 2026-03-15T05:35:59.966878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358458 | REC_0012410 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.5 | 70 | female | 0 | 16 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.6 | true | MSS | 2026-03-15T05:35:59.967151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878312 | REC_0012411 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 16.2 | 60 | female | 1 | 9 | 5.1 | 2 | entrectinib 600 mg daily | 21.2 | false | MSI-H | 2026-03-15T05:35:59.967429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554841 | REC_0012412 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.3 | 65 | female | 0 | 12 | 6.4 | 6 | osimertinib 80 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:59.967720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508266 | REC_0012413 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.1 | 69 | female | 1 | 20 | 4.3 | 6 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:59.968042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271960 | REC_0012414 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 14.3 | 77 | female | 4 | 15 | 4.3 | 6 | entrectinib 600 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:59.968413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695521 | REC_0012415 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 8.9 | 73 | female | 2 | 2 | 7.1 | 7 | osimertinib 80 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:59.968739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548167 | REC_0012416 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.2 | 71 | male | 2 | 33 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:35:59.969222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725950 | REC_0012417 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7.7 | 63 | female | 0 | 12 | 5.7 | 6 | alectinib 600 mg BID | 8.2 | false | MSS | 2026-03-15T05:35:59.969590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133830 | REC_0012418 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.5 | 79 | female | 2 | 70 | 7.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.4 | false | MSS | 2026-03-15T05:35:59.969878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672045 | REC_0012419 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 16.2 | 61 | female | 1 | 10 | 4.1 | 6 | entrectinib 600 mg daily | 9 | false | MSS | 2026-03-15T05:35:59.970183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865169 | REC_0012420 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 6 | 71 | female | 2 | 26 | 7.7 | 1 | pembrolizumab 200 mg q3w | 27.3 | false | MSS | 2026-03-15T05:35:59.970480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434268 | REC_0012421 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 7.1 | 68 | female | 0 | 18 | 2.1 | 1 | osimertinib 80 mg daily | 21.2 | false | MSS | 2026-03-15T05:35:59.970780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915630 | REC_0012422 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 23 | 12 | 61 | male | 0 | 11 | 5.7 | 0 | alectinib 600 mg BID | 46.4 | true | MSI-H | 2026-03-15T05:35:59.971078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646405 | REC_0012423 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.2 | 73 | male | 2 | 19 | 6.8 | 4 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:59.971376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884715 | REC_0012424 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 15.3 | 53 | female | 0 | 11 | 7.4 | 5 | osimertinib 80 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:59.971654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949610 | REC_0012425 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.6 | 73 | female | 2 | 59 | 8.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.9 | true | MSS | 2026-03-15T05:35:59.971938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995069 | REC_0012426 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.7 | 63 | female | 1 | 15 | 5.3 | 6 | entrectinib 600 mg daily | 6.4 | true | MSI-H | 2026-03-15T05:35:59.972374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352615 | REC_0012427 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 1.5 | 56 | female | 1 | 8 | 5.2 | 3 | entrectinib 600 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:59.972705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839007 | REC_0012428 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.7 | 69 | male | 1 | 6 | 4.9 | 2 | entrectinib 600 mg daily | 22.4 | true | MSS | 2026-03-15T05:35:59.973029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367868 | REC_0012429 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.8 | 51 | male | 0 | 17 | 4.9 | 3 | entrectinib 600 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:59.973475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677435 | REC_0012430 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.2 | 74 | female | 1 | 47 | 6.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:59.973810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661587 | REC_0012431 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 12.7 | 58 | male | 1 | 12 | 4.4 | 6 | entrectinib 600 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:59.974119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325010 | REC_0012432 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.8 | 59 | male | 1 | 16 | 3.9 | 7 | pembrolizumab 200 mg q3w | 8.5 | false | MSS | 2026-03-15T05:35:59.974422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252812 | REC_0012433 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.8 | 59 | female | 0 | 10 | 5.2 | 2 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.974718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626240 | REC_0012434 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 15.3 | 63 | male | 1 | 13 | 5 | 0 | osimertinib 80 mg daily | 47.6 | false | MSI-H | 2026-03-15T05:35:59.975009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517518 | REC_0012435 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.9 | 63 | male | 1 | 16 | 7 | 6 | alectinib 600 mg BID | 12.7 | false | MSI-H | 2026-03-15T05:35:59.975305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367321 | REC_0012436 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 13.4 | 60 | male | 0 | 27 | 5.8 | 2 | sotorasib 960 mg daily | 22.1 | true | MSI-H | 2026-03-15T05:35:59.975608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572588 | REC_0012437 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.6 | 75 | female | 1 | 8 | 6.4 | 3 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:35:59.975900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440277 | REC_0012438 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 9.3 | 75 | female | 2 | 40 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:35:59.976261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730761 | REC_0012439 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 3.6 | 68 | male | 1 | 64 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:35:59.976572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768329 | REC_0012440 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 35 | 15.2 | 70 | female | 1 | 16 | 4.9 | 5 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.976882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415464 | REC_0012441 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 1.5 | 77 | female | 2 | 17 | 5.8 | 6 | sotorasib 960 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.977183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545279 | REC_0012442 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 13.1 | 68 | male | 0 | 16 | 5.4 | 6 | alectinib 600 mg BID | 9.2 | false | MSI-H | 2026-03-15T05:35:59.977661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190812 | REC_0012443 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 6.5 | 53 | male | 0 | 55 | 7.6 | 2 | pembrolizumab 200 mg q3w | 19.7 | true | MSS | 2026-03-15T05:35:59.978017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763049 | REC_0012444 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.1 | 82 | female | 1 | 47 | 4.2 | 5 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:35:59.978385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456490 | REC_0012445 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 15.9 | 66 | male | 0 | 19 | 7 | 4 | entrectinib 600 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:59.978836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579076 | REC_0012446 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 19 | 66 | male | 1 | 20 | 5.4 | 6 | alectinib 600 mg BID | 9.5 | true | MSS | 2026-03-15T05:35:59.979197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849575 | REC_0012447 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.8 | 53 | male | 0 | 4 | 7.2 | 6 | sotorasib 960 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:59.979535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898512 | REC_0012448 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.2 | 61 | female | 1 | 8 | 6.4 | 5 | entrectinib 600 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:59.979886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692312 | REC_0012449 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 10.6 | 73 | female | 3 | 20 | 6.8 | 6 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:59.980338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679241 | REC_0012450 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 19.3 | 80 | female | 2 | 18 | 4 | 1 | osimertinib 80 mg daily | 19.4 | true | MSS | 2026-03-15T05:35:59.980756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948914 | REC_0012451 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 6.2 | 73 | female | 3 | 54 | 5.1 | 1 | pembrolizumab 200 mg q3w | 6.6 | false | MSS | 2026-03-15T05:35:59.981146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594385 | REC_0012452 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8 | 64 | female | 0 | 9 | 7.5 | 8 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:59.981523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107069 | REC_0012453 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 10.6 | 81 | female | 1 | 7 | 6 | 5 | pembrolizumab 200 mg q3w | 12.1 | true | MSI-H | 2026-03-15T05:35:59.981891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186191 | REC_0012454 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 6.4 | 87 | female | 1 | 15 | 4.6 | 3 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:59.982297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322550 | REC_0012455 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8 | 80 | female | 1 | 4 | 6 | 8 | alectinib 600 mg BID | 16.3 | false | MSS | 2026-03-15T05:35:59.982821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116979 | REC_0012456 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 31 | 14.3 | 90 | female | 1 | 15 | 4.3 | 0 | entrectinib 600 mg daily | 29.2 | false | MSS | 2026-03-15T05:35:59.983249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621476 | REC_0012457 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 2.6 | 85 | male | 1 | 18 | 5 | 2 | alectinib 600 mg BID | 10.2 | false | MSS | 2026-03-15T05:35:59.983630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933335 | REC_0012458 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 8.1 | 66 | male | 1 | 40 | 2 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:35:59.983999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819129 | REC_0012459 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.4 | 74 | female | 0 | 3 | 4.9 | 6 | osimertinib 80 mg daily | 16 | true | MSS | 2026-03-15T05:35:59.984429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317386 | REC_0012460 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.6 | 57 | male | 1 | 13 | 4.1 | 6 | entrectinib 600 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:59.984783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464115 | REC_0012461 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12.5 | 69 | female | 1 | 16 | 4.6 | 1 | osimertinib 80 mg daily | 22.5 | false | MSI-H | 2026-03-15T05:35:59.985120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223204 | REC_0012462 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 8.8 | 61 | female | 0 | 13 | 4.1 | 2 | sotorasib 960 mg daily | 15 | false | MSS | 2026-03-15T05:35:59.985478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979970 | REC_0012463 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 15.2 | 71 | female | 3 | 16 | 3.4 | 5 | osimertinib 80 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:59.985821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366915 | REC_0012464 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 16.4 | 77 | female | 1 | 15 | 3.6 | 2 | sotorasib 960 mg daily | 17.5 | false | MSI-H | 2026-03-15T05:35:59.986165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682660 | REC_0012465 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 6.8 | 66 | female | 0 | 4 | 5 | 6 | entrectinib 600 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:59.986475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697061 | REC_0012466 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.4 | 58 | male | 0 | 10 | 7 | 6 | osimertinib 80 mg daily | 10 | true | MSI-H | 2026-03-15T05:35:59.986798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429631 | REC_0012467 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.6 | 72 | female | 0 | 23 | 5.3 | 5 | pembrolizumab 200 mg q3w | 4.8 | false | MSS | 2026-03-15T05:35:59.987111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396815 | REC_0012468 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.5 | 76 | female | 1 | 10 | 6.3 | 10 | alectinib 600 mg BID | 11.9 | true | MSS | 2026-03-15T05:35:59.987565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925254 | REC_0012469 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 11.1 | 66 | female | 0 | 11 | 5 | 2 | osimertinib 80 mg daily | 22 | false | MSI-H | 2026-03-15T05:35:59.987936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104084 | REC_0012470 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 25 | 7.3 | 77 | male | 2 | 37 | 5.9 | 0 | pembrolizumab 200 mg q3w | 45 | false | MSS | 2026-03-15T05:35:59.988410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299835 | REC_0012471 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 7.2 | 60 | female | 1 | 9 | 7 | 6 | entrectinib 600 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:59.988803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450750 | REC_0012472 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.3 | 67 | female | 1 | 17 | 5.8 | 4 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:59.989172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670876 | REC_0012473 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6 | 67 | female | 0 | 39 | 4.3 | 5 | pembrolizumab 200 mg q3w | 10.5 | true | MSS | 2026-03-15T05:35:59.989554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198696 | REC_0012474 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.1 | 80 | female | 2 | 10 | 3.8 | 6 | alectinib 600 mg BID | 12.9 | false | MSI-H | 2026-03-15T05:35:59.989923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151506 | REC_0012475 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.3 | 67 | female | 0 | 22 | 6.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:59.990294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886919 | REC_0012476 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.8 | 75 | female | 2 | 22 | 4.4 | 1 | sotorasib 960 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:59.990616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277211 | REC_0012477 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16.1 | 73 | female | 2 | 22 | 5.8 | 2 | osimertinib 80 mg daily | 12.7 | true | MSI-H | 2026-03-15T05:35:59.990942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419318 | REC_0012478 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 15.7 | 54 | female | 0 | 23 | 6.9 | 5 | entrectinib 600 mg daily | 8.9 | true | MSI-H | 2026-03-15T05:35:59.991249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407798 | REC_0012479 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 15.5 | 71 | male | 3 | 17 | 4.8 | 5 | pembrolizumab 200 mg q3w | 8.2 | false | MSI-H | 2026-03-15T05:35:59.991559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497845 | REC_0012480 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 2.3 | 65 | female | 1 | 45 | 2.7 | 1 | pembrolizumab 200 mg q3w | 26.8 | true | MSS | 2026-03-15T05:35:59.991863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893115 | REC_0012481 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 12.4 | 72 | female | 1 | 6 | 6.6 | 5 | osimertinib 80 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:35:59.992529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673145 | REC_0012482 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 9 | 73 | female | 1 | 15 | 2.9 | 1 | alectinib 600 mg BID | 14.5 | true | MSS | 2026-03-15T05:35:59.992926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482003 | REC_0012483 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 7 | 71 | female | 1 | 13 | 5.2 | 1 | alectinib 600 mg BID | 20.8 | true | MSS | 2026-03-15T05:35:59.993247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145462 | REC_0012484 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.4 | 53 | female | 0 | 19 | 6.3 | 5 | sotorasib 960 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:59.993552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122845 | REC_0012485 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.7 | 65 | female | 1 | 55 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.5 | false | MSS | 2026-03-15T05:35:59.993855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280577 | REC_0012486 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 12.7 | 69 | male | 1 | 17 | 6.3 | 3 | sotorasib 960 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.994178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428496 | REC_0012487 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.7 | 65 | female | 0 | 20 | 5.6 | 4 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:35:59.994497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271472 | REC_0012488 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 19.2 | 57 | male | 1 | 14 | 5.4 | 7 | sotorasib 960 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:59.994820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602556 | REC_0012489 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.7 | 75 | male | 1 | 0 | 5.9 | 1 | alectinib 600 mg BID | 20.5 | false | MSS | 2026-03-15T05:35:59.995141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404058 | REC_0012490 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 5.4 | 74 | female | 1 | 9 | 5.6 | 6 | alectinib 600 mg BID | 5.7 | false | MSS | 2026-03-15T05:35:59.995453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382109 | REC_0012491 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.9 | 70 | female | 2 | 51 | 7.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.1 | true | MSS | 2026-03-15T05:35:59.995753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852637 | REC_0012492 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 16.9 | 75 | female | 2 | 10 | 6.8 | 2 | entrectinib 600 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:59.996057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623494 | REC_0012493 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.7 | 71 | female | 1 | 19 | 7.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 26.5 | false | MSS | 2026-03-15T05:35:59.996584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447894 | REC_0012494 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 37 | 6.8 | 55 | female | 1 | 10 | 5.3 | 4 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:35:59.997180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143939 | REC_0012495 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 6.2 | 55 | female | 0 | 45 | 5.9 | 1 | pembrolizumab 200 mg q3w | 15.3 | false | MSS | 2026-03-15T05:35:59.997607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300674 | REC_0012496 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.9 | 66 | female | 0 | 22 | 5.4 | 5 | alectinib 600 mg BID | 12.1 | true | MSS | 2026-03-15T05:35:59.997992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910591 | REC_0012497 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 6.4 | 72 | male | 2 | 24 | 4.1 | 1 | alectinib 600 mg BID | 19.1 | false | MSS | 2026-03-15T05:35:59.998368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444742 | REC_0012498 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.6 | 79 | female | 2 | 7 | 4.6 | 4 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:59.998720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376691 | REC_0012499 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 6.6 | 63 | male | 0 | 17 | 5.5 | 6 | sotorasib 960 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:59.999053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365877 | REC_0012500 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 6.1 | 72 | female | 1 | 3 | 4 | 1 | alectinib 600 mg BID | 19.1 | false | MSS | 2026-03-15T05:35:59.999377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.